“We Are On The Cusp Of A Real Revolution”: OHC Rare Disease Center Boosts Innovation
Matthew Wood, director and chief scientific officer at Oxford-Harrington Rare Disease Center, discusses the state of rare disease R&D, the evolving la...
Scrip Awards Podcast, 2025 Winners
This podcast brings you highlights from Scrip Awards 2025, including wins for AstraZeneca, Syndax, Akeso and Summit Therapeutics and the Lifetime Achi...
Datamonitor Healthcare Podcast: A Deep Dive into Dry AMD
Emma Wille and Summer Colling speak with ophthalmology expert, Joseph Jacob, to discuss the latest developments in dry age-related macular degeneratio...
Scrip M&A Podcast: PwC's Dealmaking Preview for 2026
Scrip senior writer Joseph Haas and PwC analyst Roel Van den Akker look back on biopharma sector dealmaking in 2025, why deal values rose from 2024's ...
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2025年12月12日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本期聚焦美国血液学会（ASH）会议五大关键成果：Jaypirca有望成为一线疗法；Kite公司Anito-cel在多发性骨髓瘤领域的进展；新一...
Scrip's Five Must-Know Things - Dec. 15, 2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended December 12, 2025. This week, a focus on five key results...
Scrip 五件必知要闻: 药闻周析 - 全球制药风云聚焦 (Chinese-language podcast)
本期播客内容来自《Scrip》杂志，精选内容涵盖截至2025年12月5日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。 本次要闻: 特朗普在英国药品定价谈判中获胜；诺和诺德阐释司美格鲁肽治疗阿尔茨海默病的依据；强生与诺华达成年度最大并购交易；CAR-T疗法成效参差...
Scrip's Five Must-Know Things - Dec. 8, 2025
Audio roundup of selected biopharma industry content from Scrip over the business week ended December 5, 2025. In this episode: Trump’s UK drug pricin...
Overcoming Drug Resistance In Oncology With Kairos Pharma's Neil Bhowmick
Drug resistance derails even the most advanced cancer treatments, but what if we could restore sensitivity to existing therapies instead of starting o...
Drug Fix: Understanding the US FDA’s CDER Leadership Shuffle
Pink Sheet Executive Editor Derrick Gingery, Senior Writer Sarah Karlin-Smith and Editor-in-Chief Nielsen Hobbs break down the pending retirement of C...